- Associated Press - Tuesday, December 13, 2016

Johnson & Johnson said Tuesday it has ending talks to buy Swiss drugmaker Actelion Pharmaceuticals.

The New Brunswick, New Jersey-based health care giant said it was unable to reach a deal that would have created “adequate value” for its shareholders. Last month, it said the two were in early-stage talks about a possible deal.

Actelion late Tuesday confirmed the negotiations with Johnson & Johnson had been broken off. It added, however, that it was in talks “another party regarding a possible strategic transaction.” It gave no further details.

Johnson & Johnson develops drugs and makes medical devices and other consumer products. It is behind such brands as Band-Aids, Tylenol and biologic immune disorder drug Remicade.

Actelion Pharmaceuticals Ltd. makes high blood pressure medicines that treat arteries in the lung and around the heart.

Copyright © 2018 The Washington Times, LLC.

The Washington Times Comment Policy

The Washington Times is switching its third-party commenting system from Disqus to Spot.IM. You will need to either create an account with Spot.im or if you wish to use your Disqus account look under the Conversation for the link "Have a Disqus Account?". Please read our Comment Policy before commenting.

 

Click to Read More

Click to Hide